Parkinson’s disease: Prexton Therapeutics starts phase 1 clinical trial

08.03.2016 08:17
Nervensystem

Prexton Therapeutics, a biopharmaceutical company founded in 2012, applies a new scientific approach that fully integrates molecular, behavioral and chemistry technologies to address Parkinson’s disease and other brain disorders. The company has announced the launch of a phase 1 clinical trial. The trial should be complete by mid 2016, with results expected in August 2016.

Prexton’s innovative approach in the treatment of Parkinson’s is unique as it stimulates a compensatory neuronal system that is not impacted by the disease. Competitors in this area mostly target the dopaminergic system, which does not address all symptoms and is accompanied by a number of adverse effects. Prexton’s compound activates a specific target of the glutamatergic system, with the goal of providing a robust therapeutic effect without the occurrence of adverse events. Thus, Prexton’s first in class treatment has the potential to offer a better benefit/risk ratio for Parkinson’s patients than existing therapies.

The company aims to develop a group of first-in-class molecules that target the metabotropic Glutamate Receptor 4 (mGluR4), a protein belonging to the metabotropic glutamate receptor family. Preclinical data shows compelling evidence of efficacy for Prexton’s molecule. It has the potential to alleviate motor complications by modulating glutamate over activity in the central nervous system of Parkinson patients.

The phase 1 trial will include 72 subjects given ascending doses of the molecule, administered orally. The primary endpoint is to assess tolerability in healthy volunteers.

Prexton relies on a team of experienced researchers with expertise in CNS. The study will be financed by a $10 million (€8.86m) series A funding that closed in February 2015.

“We are delighted to launch this phase 1 clinical trial. We look forward to assessing the tolerability and safety of our first molecule and later to demonstrate the effectiveness of our treatment in Parkinson’s disease,” said François Conquet, CEO of Prexton Therapeutics. “Prexton is the leading company developing mGluR4 compounds for Parkinson’s. This study will further strengthen our position in the treatment of Parkinson’s disease.”

(Press release)

Comments

Please login or sign up to comment. Commenting guidelines

Please login or
register to use the
bookmark feature

Related News

Principal

Opportunities and support for Vaud-based start-up and SMEs

The SPECo and Seedstars are organising a kick-off event to inform Vaud-based companies about their new initiative and prospects. Register until 30 September 2016.

 

 

Partners

Contributors